Compare TOP & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOP | IPSC |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.8M | 189.7M |
| IPO Year | 2021 | 2021 |
| Metric | TOP | IPSC |
|---|---|---|
| Price | $1.01 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 37.4K | ★ 896.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.07 |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $6,589,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.14 |
| Revenue Growth | N/A | ★ 194.81 |
| 52 Week Low | $0.94 | $0.34 |
| 52 Week High | $3.33 | $2.71 |
| Indicator | TOP | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 75.09 |
| Support Level | $1.00 | $0.49 |
| Resistance Level | $1.12 | N/A |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 40.00 | 93.40 |
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.